Halozyme Therapeutics, Inc. (HALO) Guidance & Earnings Results

On 2026-08-06 Halozyme Therapeutics, Inc. raised guidance: "Revenue $1.835-$1.910B (+31-37% YoY), Royalty $1.220-$1.245B (+41-43% YoY), Adj. EBITDA $1.225-$1.280B (+86-95% YoY), Non-GAAP EPS $8.65-$9.00 (+108-117%…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HALOHalozyme Therapeutics, Inc.Follow HALO — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 14.3B
P/E TTM: 36.6
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Raised	Revenue $1.835-$1.910B (+31-37% YoY), Royalty $1.220-$1.245B (+41-43% YoY), Adj. EBITDA $1.225-$1.280B (+86-95% YoY), Non-GAAP EPS $8.65-$9.00 (+108-117% YoY) · full year
11 May 26	Reaffirmed	Total Revenue $1.710-$1.810B (22%-30% growth), Royalty Revenue $1.130-$1.170B (30%-35% growth), Adjusted EBITDA $1.125-$1.205B (71%-83% growth), Non-GAAP Diluted EPS $7.75-$8.25 (87%-99% growth) · full year
17 Feb 26	Raised	2026 Total Revenue guidance of $1.71-1.81B (+22-30% YoY); Adj. EBITDA $1.125-1.205B (+71-83%)
28 Jan 26	Raised	2026 total revenue $1.71-1.81B (+23-30% YoY); royalty revenue $1.13-1.17B (+30-35% YoY); adjusted EBITDA $1.125-1.205B; non-GAAP EPS $7.75-8.25
3 Nov 25	Raised	FY2025 revenue guidance raised to $1.3-1.375B, Adjusted EBITDA to $885-935M · full year
5 Aug 25	Raised	FY25 total revenue raised to $1,275M-$1,355M from $1,200M-$1,280M; FY25 royalty revenue raised to $825M-$860M from $750M-$785M; FY25 adjusted EBITDA raised to $865M-$915M from $790M-$840M; FY25 non-GAAP diluted EPS raised to $6.00-$6.40 from $5.30-$5.70 · full year

Halozyme Therapeutics, Inc. — questions

What guidance did Halozyme Therapeutics, Inc. give?: On 2026-08-06: "Revenue $1.835-$1.910B (+31-37% YoY), Royalty $1.220-$1.245B (+41-43% YoY), Adj. EBITDA $1.225-$1.280B (+86-95% YoY), Non-GAAP EPS $8.65-$9.00 (+108-117% YoY)"
When does Halozyme Therapeutics, Inc. report earnings?: Halozyme Therapeutics, Inc.'s next earnings report is expected on 2026-11-05.

Every figure on this page comes from Halozyme Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.